相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma
Mariarosaria Marseglia et al.
CANCERS (2021)
Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients
A. N. Shoushtari et al.
ANNALS OF ONCOLOGY (2021)
Overall survival benefit from tebentafusp in patients with best response of progressive disease.
Anthony M. Joshua et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.
Marlana Orloff et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Role of Immune Checkpoint Blockade in Uveal Melanoma
Anja Wessely et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Single-cell analysis reveals new evolutionary complexity in uveal melanoma
Michael A. Durante et al.
NATURE COMMUNICATIONS (2020)
An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis
Rino S. Seedor et al.
CANCERS (2020)
Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma
Mizue Terai et al.
CANCERS (2020)
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Yana G. Najjar et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma
Mark R. Middleton et al.
CLINICAL CANCER RESEARCH (2020)
Treatment of Metastatic Uveal Melanoma: Systematic Review
Cristina Rodriguez-Vidal et al.
CANCERS (2020)
A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)
J. J. Sacco et al.
ANNALS OF ONCOLOGY (2020)
Vitiligo and other clinical melanocyte-related adverse events following tebentafusp (IMCgp100) exposure in patients with uveal melanoma
Marlana Orloff et al.
CANCER RESEARCH (2020)
Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).
Jessica Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
Meredith Pelster et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma
Bertil E. Damato et al.
CANCERS (2019)
Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types
Monique K. van der Kooij et al.
CANCERS (2019)
Immunological Backbone of Uveal Melanoma: Is There a Rationale for Immunotherapy?
Ernesto Rossi et al.
CANCERS (2019)
Molecular Characteristics of Uveal Melanoma: Insights from the Cancer Genome Atlas (TCGA) Project
Mathieu E. Bakhoum et al.
CANCERS (2019)
1355PTumour mutational burden and response to PD-1 inhibitors: An analysis of 89 cases of metastatic melanoma
L Dousset et al.
ANNALS OF ONCOLOGY (2019)
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Mark Yarchoan et al.
JCI INSIGHT (2019)
Bispecific antibodies for cancer therapy: A review
Anuradha Krishnamurthy et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings
Takami Sato et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma
Asad Javed et al.
IMMUNOTHERAPY (2017)
Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies
Alain P. Algazi et al.
CANCER (2016)
Efficacy of nivolumab and ipilimumab (Nivo plus Ipi) combination in melanoma patients (pts) treated at a single institution on an expanded-access program (EAP).
Alexander Noor Shoushtari et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma
Mark R. Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naive Patients with Metastatic Uveal Melanoma
Lisa Zimmer et al.
PLOS ONE (2015)
Metastasis with a little help from MDSCs
Victoria Aranda
NATURE MEDICINE (2011)
Screening for metastasis from choroidal melanoma: The Collaborative Ocular Melanoma Study Group report 23
M Diener-West et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
